Key Takeaways
- • Apposite Capital completed its first exit from Healthcare III fund through the sale of CrestOptics to Evident, marking a significant milestone for the fund.
- • CrestOptics, founded in 2011 and based in Rome, specializes in optical imaging systems for spinning disk confocal and super-resolution microscopy applications.
- • The transaction represents a successful realization of value for Apposite Capital's healthcare-focused investment strategy.
Summary
Apposite Capital has announced the completion of its first exit from its Healthcare III fund, with the sale of CrestOptics to Evident. The transaction underscores Apposite's track record in identifying and scaling healthcare technology investments within its dedicated fund vehicle.
CrestOptics, established in 2011 in Rome, develops and manufactures advanced optical imaging systems tailored for spinning disk confocal and super-resolution microscopy. The company's technology serves the scientific research and life sciences instrumentation markets, addressing demand for high-precision imaging solutions used in laboratory and clinical research environments.
The sale to Evident represents a successful value realization for Apposite Capital's Healthcare III investors and validates the fund's investment thesis in specialized medical technology companies. While specific transaction valuations and terms were not disclosed, the exit demonstrates Apposite's ability to execute exits in the healthcare technology sector and return capital to its limited partners.
CrestOptics, established in 2011 in Rome, develops and manufactures advanced optical imaging systems tailored for spinning disk confocal and super-resolution microscopy. The company's technology serves the scientific research and life sciences instrumentation markets, addressing demand for high-precision imaging solutions used in laboratory and clinical research environments.
The sale to Evident represents a successful value realization for Apposite Capital's Healthcare III investors and validates the fund's investment thesis in specialized medical technology companies. While specific transaction valuations and terms were not disclosed, the exit demonstrates Apposite's ability to execute exits in the healthcare technology sector and return capital to its limited partners.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.